Stockscreener 앱 받기
10.16
3.24%
-0.34
Day One Biopharmaceuticals Inc 주식(DAWN)의 최신 뉴스
Earnings Beat: How does Day One Biopharmaceuticals Inc compare to its peersJuly 2025 Gainers & Low Volatility Stock Recommendations - baoquankhu1.vn
First Week of March 20th Options Trading For Day One Biopharmaceuticals (DAWN) - Nasdaq
Growth Recap: How does Day One Biopharmaceuticals Inc compare to its peers2025 Earnings Impact & Daily Chart Pattern Signals - baoquankhu1.vn
Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 107.36%: Read This Before Placing a Bet - sharewise.com
Update Report: Is Day One Biopharmaceuticals Inc a top pick in the sectorQuarterly Risk Review & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Retail Trends: Can Day One Biopharmaceuticals Inc generate free cash flow2025 Big Picture & Fast Entry Momentum Alerts - baoquankhu1.vn
Rally Mode: How geopolitical tensions affect Day One Biopharmaceuticals Inc stockLayoff News & Daily Chart Pattern Signals - Bộ Nội Vụ
Day One Biopharmaceuticals (NASDAQ:DAWN) Trading Down 10.1%What's Next? - MarketBeat
Day One Biopharmaceuticals (NASDAQ:DAWN) Earns Buy Rating from Analysts at TD Cowen - MarketBeat
Day One Biopharmaceuticals (DAWN) Surges 26.7%: Is This an Indication of Further Gains? - Yahoo Finance
A Look At Day One Biopharmaceuticals (DAWN) Valuation After Strong OJEMDA Revenue And 2026 Outlook Updates - Yahoo Finance
Day One Biopharmaceuticals stock initiated with Buy rating at TD Cowen - Investing.com Canada
DAWN: OJEMDA's growth and new pipeline assets set the stage for significant revenue expansion in 2026 - TradingView — Track All Markets
Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance - Sahm
Day One Biopharmaceuticals (NASDAQ:DAWN) Shares Gap UpTime to Buy? - MarketBeat
Gold Rises Sharply; Lyra Therapeutics Shares Plunge - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Planet Labs PBC, Day One Biopharmaceuticals, Rxsight, SunOpta And Other Big Stocks Moving Higher On Monday - Benzinga
Day One Biopharmaceuticals stock soars after strong 2025 revenue forecast By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Day One Biopharmaceuticals Reports 172% Year-over-Year Growth in 2025 Net Product Revenue, Projects 2026 Revenue Between $225 Million and $250 Million - Quiver Quantitative
Day One says Ojemda 2026 U.S. net product revenue projected to be $225$250 million - marketscreener.com
Cancer drug OJEMDA sales jump 172% in 2025 as Day One sets 2026 target - Stock Titan
Behavioral Patterns of DAWN and Institutional Flows - Stock Traders Daily
Day One Biopharmaceuticals Stock Pre-Market (+5.4%) : Market Digests Mersana Acquisition - Trefis
How to contact the Daily Bulletin - FinancialContent
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Day One Biopharmaceuticals, Inc.Common Stock (NQ: DAWN - FinancialContent
Will Day One Biopharmaceuticals Inc. stock benefit from automationQuarterly Market Summary & Reliable Momentum Entry Alerts - ulpravda.ru
Trading Action: Is Day One Biopharmaceuticals Inc. stock a good choice for value investorsWall Street Watch & Technical Buy Zone Confirmation - Улправда
How The Day One Deal Is Reshaping The Story For Mersana Therapeutics (MRSN) - Yahoo Finance
Day One concludes Mersana Therapeutics acquisition - Yahoo Finance
Day One Biopharmaceuticals completes acquisition of Mersana Therapeutics By Investing.com - Investing.com Australia
Day One Biopharmaceuticals completes acquisition of Mersana Therapeutics - Investing.com
Day One Biopharmaceuticals Completes Acquisition of Mersana Therapeutics - TipRanks
Day One Biopharmaceuticals Signs Contingent Value Rights Agreement With Computershare - TradingView — Track All Markets
Day One Biopharmaceuticals Completes Acquisition of Mersana Therapeutics to Enhance Oncology Pipeline - Quiver Quantitative
Day One Completes Acquisition of Mersana Therapeutics - GlobeNewswire
About Us | Laser Focus WorldDay One Completes Acquisition of Mersana Therapeutics - FinancialContent
Oklahoma City NewsThe OklahomanDay One Completes Acquisition of Mersana Therapeutics - FinancialContent
Day One Biopharmaceuticals (NASDAQ:DAWN) Nasdaq Index Biomarker Science - Kalkine Media
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
(DAWN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
When Can We Expect A Profit From Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)? - 富途牛牛
How The Mersana Deal Is Rewriting The Story Behind Day One Biopharmaceuticals Valuation - Yahoo Finance
Is Day One Biopharmaceuticals Inc. stock dividend yield sustainableJuly 2025 Trends & Growth Focused Stock Pick Reports - Улправда
Price-Driven Insight from (DAWN) for Rule-Based Strategy - Stock Traders Daily
Day One Biopharmaceuticals (NASDAQ:DAWN) Stock Price Down 6%What's Next? - MarketBeat
We Think Day One Biopharmaceuticals (NASDAQ:DAWN) Can Easily Afford To Drive Business Growth - Sahm
Day One Pharmaceuticals: Stock Surges Ahead Of Promising 2026I'm Bullish (NASDAQ:DAWN) - Seeking Alpha
Day One Biopharmaceuticals (NASDAQ:DAWN) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Day One Biopharmaceuticals Reports Promising FIREFLY-1 Trial Results - timothysykes.com
FuelCell Energy Posts Strong Q4 Results, Joins Trump Media & Technology, Micron Technology, Lululemon And Other Big Stocks Moving Higher On Thursday - Sahm
Day One Biopharmaceuticals (NASDAQ:DAWN) Trading Up 5.5%Still a Buy? - MarketBeat
Day One Biopharmaceuticals Target of Unusually Large Options Trading (NASDAQ:DAWN) - MarketBeat
Day One Biopharma (DAWN) announces positive 3-year follow-up results from pivotal phase 2 FIREFLY-1 trial of OJEMDA (tovorafenib) - MSN
Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Hudson Bay Capital Management LP Has $8.43 Million Holdings in Day One Biopharmaceuticals, Inc. $DAWN - MarketBeat
Day One Biopharma (DAWN) Announces Positive 3-Year Follow-up Results from Pivotal Phase 2 FIREFLY-1 Trial of OJEMDA (Tovorafenib) - Finviz
4.73%
0.92%
자본화:
|
볼륨(24시간):